1. 89PPre-clinical evaluation of bifunctional SIRPα-antibody fusion proteins for the treatment of acute myeloid leukemia. (17th December 2018) Authors: Pascual Ponce, L; Heitmüller, C; Kozik, J-H; Subklewe, M; Fenn, N C; Hopfner, K-P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. L4 Synthetic agonistic receptor-activating BiTEs – a modular platform for the efficient targeting of acute myeloid leukemia. (1st October 2020) Authors: Benmebarek, M; Cadilha, BL; Hermann, M; Lesch, S; Augsburger, C; Brauchle, B; Stoiber, S; Darwich, A; Rataj, F; Klein, C; Hopfner, K; Subklewe, M; Endres, S; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OS03.4.A In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer. (5th September 2022) Authors: Xu, T; Karschnia, P; Cadilha, B; Dede, S; Lorenz, M; Seewaldt, N; Nikolaishvili, E; Müller, K; Blobner, J; Teske, N; Langer, S; Obeck, H; Lorenzini, T; Mulazzani, M; Zhang, W; Ishikawa-Ankerhold, H; Buchholz, V R; Subklewe, M; Thon, N; Straube, A Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P02.01 Predictive impact of the gut microbiota on treatment response to CD19 specific CAR T-cells. (1st October 2020) Authors: Blumenberg, V; Zamir, E; Schmidt, S; Gaiser, R; Cullin, N; Bücklein, V; Schmidt, C; von Bergwelt, M; Elinav, E; Stein-Thoeringer, CK; Subklewe, M Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P04.04 Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML. (1st October 2020) Authors: Schmitt, S; Lohner, A; Deiser, K; Maiser, A; Rothe, M; Augsberger, C; Moosmann, A; Leonhardt, H; Fenn, N; Griffioen, M; Hopfner, K; Subklewe, M Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P04.09 Development of a dendritic cell vaccine against hepatocellular carcinoma using VSV-NDV. (1st October 2020) Authors: Gold, J; Hanesch, L; Krabbe, T; Lozano-Simon, C; Hänel, G; Rothe, M; Klopp, A; Göttert, S; Heidegger, S; Protzer, U; Subklewe, M; Altomonte, J Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P07.01 CD19 CAR T-cells for relapsed/refractory diffuse large B-cell Lymphoma: real-world data from LMU Munich. (1st October 2020) Authors: Bücklein, V; Blumenberg, V; Schmidt, C; Rejeski, K; Ruzicka, M; Müller, N; Reischer, A; von Baumgarten, L; Völkl, A; Wagner, B; Humpe, A; Tischer, J; Stemmler, H; von Bergwelt, M; Subklewe, M Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P08.05 Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia. (21st September 2022) Authors: Nair, R; Sponheimer, M; Salinas-Illarena, A; Côrte-Real, JV; Subklewe, M; Baldauf, HM Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P09.01 Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia. (21st September 2022) Authors: Gottschlich, A; Thomas, M; Grünmeier, R; Lesch, S; Rohrbacher, L; Igl, V; Briukhovetska, D; Benmebarek, M; Dede, S; Müller, K; Xu, T; Dhoqina, D; Umut, Ö; Märkl, F; Robinson, S; Sendelhofert, A; Schulz, H; Vick, B; Cadilha, BL; Brabenec, R Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P09.02 Modular P329G-binding CAR T cells engineered to recognize human effector-silenced antibodies carrying a P329G Fc-mutation for targeting of solid tumor antigens. (21st September 2022) Authors: Stock, S; Benmebarek, M; Kluever, A; Darowski, D; Jost, C; Stubenrauch, K; Benz, J; Freimoser-Grundschober, A; Moessner, E; Umana, P; Subklewe, M; Endres, S; Klein, C; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗